coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Rural North Chichester PCN, Chichester · Health Inequalities Profile

    PCN U33593 · NHS Surrey and Sussex Integrated Care Board; NHS Sussex Integrated Care Board · 4 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    39,128

    Registered population

    53.1% aged 18–64

    30.8%

    Aged 65+

    ICB 21.9% · England 17.9%

    3.4%

    Ethnic minority (non-White)

    1.1% Asian · England 9.6%

    0.0%

    In IMD quintile 1

    ICB 9.2% · England 21.0%

    0

    Core20 residents (est.)

    Resident basis; registered basis 0 · see page 3

    7,086

    Hypertension register

    +6.01% in 3 yrs · England +5.60%

    309

    SMI register

    25.4% of Chichester's

    704

    COPD register

    Reviews -2.49% in 3 yrs

    Forecast to 2030

    8,406

    Hypertension patients, 2030

    +1,320 on today

    80.3%

    QRISK ≥20% on statins, 2030

    +8.00pp over 3 yrs

    7.7%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    64.4%
    Asthma annual review coverage trails benchmarks.

    Reviews reached 64.4% (Chichester 67.5%, England 65.7%), leaving about 950 of 2,666 patients unreviewed, which may reflect recall capacity to test locally.

    60.5%
    High-risk lipid therapy below England rate.

    Despite +15.2% three-year growth, lipid therapy for QRISK ≥ 20% is 60.5% against 63.6% in England, which could reflect recall gaps to audit.

    73.0%
    Strong hypertension control and heart failure reviews.

    Hypertension treatment to target is 73.0% (England 70.3%) and annual heart failure reviews reach 90.6% (Chichester 82.2%, England 78.5%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Patients aged 65 and over comprise 30.8% of the registered list, exceeding benchmarks

    Rural North Chichester PCN registers 39,128 patients. Across the network, 30.8% (12,062 patients) are aged 65 and over, exceeding Chichester (26.9%), NHS Sussex Integrated Care Board (21.9%), and England (17.9%). Patients aged 0-17 comprise 16.0% (6,273 patients; Chichester 17.3%, NHS Sussex Integrated Care Board 17.7%, England 19.6%). Based on Census usual residents rather than GP registrations, 96.7% are White, above Chichester (95.4%), NHS Sussex Integrated Care Board (91.0%), and England (81.1%), with a 3.4% ethnic minority share.

    Age profile

    0–1716.0%
    18–6453.1%
    65+30.8%

    65+: ICB 21.9%, England 17.9%

    Ethnicity

    White96.7%
    Mixed1.5%
    Asian1.1%
    Black0.3%
    Other0.3%

    Older people · falls rows are Chichester local-authority (LA) data, not PCN

    MeasureLocalSouth EastEnglandPeriod
    Falls admissions, 65+, per 100,000 (Chichester LA)2,4532,0181,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)79.2%82.2%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)64.0%57.8%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Chichester LA)1,2859819552024/25
    Falls deaths, all ages, per 100,000 (Chichester LA)8.714.014.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Zero registered patients live in Core20 areas, with an average IMD decile of 6.7

    Rural North Chichester PCN records 0.0% of registered patients in the Core20 cohort (Chichester 0.0%, NHS Sussex Integrated Care Board 9.2%, England 21.0%). Its average IMD decile is 6.7 (Chichester 6.2, NHS Sussex Integrated Care Board 6.1, England 5.5). All four practices—The Petworth Surgery, Pulborough Medical Group, Loxwood Surgery, and Riverbank Medical Centre—record a 0.0% Core20 share (0 estimated patients). Average IMD deciles are 5.5 at The Petworth Surgery and 7.6 at Pulborough Medical Group. Zero Core20 concentration means outreach must address dispersed rural vulnerability directly.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Petworth0.0% · 0 patients
    Pulborough0.0% · 0 patients
    Loxwood0.0% · 0 patients
    Riverbank0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    309

    SMI register

    0.78% recorded prevalence

    172

    Learning disability register

    0.44% recorded prevalence

    11

    Care homes, 465 beds

    In the PCN catchment

    8.5%

    Provide unpaid care

    Chichester, Census 2021

    The PCN records 309 severe mental illness patients (0.8%; Chichester 1.0%, NHS Sussex Integrated Care Board 1.1%, England 1.0%) and 172 learning disability patients (0.4%; Chichester 0.6%, NHS Sussex Integrated Care Board 0.6%, England 0.6%). Catchment facilities include 11 care homes with 465 beds. Lower learning disability prevalence than benchmarks could reflect coding or case-mix differences to test through practice register audits.

    Severe mental illness: physical health checks

    Annual SMI blood pressure checks reached 85.7% (England 83.4%) and BMI checks 86.5% (England 82.1%). Three-year blood pressure gains (+2.6 pp) trailed England (+4.4 pp) across 309 patients. Proactive recall is needed to sustain physical health monitoring.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    7,086

    Hypertension register

    +6.01%

    Register growth, 3 yrs

    Chichester +5.87% · England +5.60%

    +5.73pp

    BP control, under 80

    ≤140/90 · +1.87pp aged 80+

    +1,320

    More patients by 2030

    Forecast 8,406 (20.23%)

    Hypertension case-finding and control

    Hypertension prevalence is 18.0% (7,086 patients), above Chichester (17.4%), NHS Sussex ICB (16.3%) and England (15.2%). Blood pressure treated to target reaches 73.0% (England 70.3%), and heart failure reviews reach 90.6% (England 78.5%). However, recent blood pressure monitoring is 89.1%, trailing Chichester (91.6%) and England (90.0%), while 3-year change of +1.9% lagged England (+3.6%). Stroke prevalence is 2.5% (976 patients; Chichester 2.5%, England 1.9%), but 3-year change was -0.8% while England changed +2.3%; whether this reflects coding shifts or mortality changes is unverified locally. Trailing monitoring rates alongside high treatment achievement indicate an opportunity to systematise annual blood pressure reviews so controlled patients do not slip from target.

    Lipids and statins

    Lipid-lowering therapy for patients with QRISK ≥ 20% reaches 60.5%, trailing England (63.6%) despite a +15.2% 3-year change (England +6.2%), while matching Chichester (60.4%). Lower high-risk uptake than England implies an opportunity to prioritise risk-score recall across primary prevention cohorts.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 2026118,241£2.00£2.42£1.86£236,482
    Cardiovascular (all), 2025132,697£3.47£3.32£3.33£460,459

    In 2026, lipid-regulating drugs cost £2.00 per item across 118,241 items (England £1.86, Chichester £2.11, NHS Sussex ICB £2.42). Across these items, the PCN spends £16,554 more than at England's unit cost, but £49,661 less than at NHS Sussex Integrated Care Board's unit cost. Higher unit costs than England suggest formulary review could reduce expenditure without compromising lipid-lowering treatment reach.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    −0.13%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +0.54%

    Asthma prevalence, PCN 3-yr % change

    Annual asthma reviews reached 64.4% across 2,666 patients, trailing Chichester (67.5%) and England (65.7%), as three-year progress fell 0.1% (England +4.4%), leaving about 950 patients unreviewed. Second-hand smoke recording for ages 6–19 was 74.1% (England 78.8%). COPD prevalence 3-year change was +7.8% to 704 patients (1.8%), but annual reviews fell 2.5% over three years (England +2.8%), despite current achievement of 77.1%. Stalled reviews and a 3.8 pp drop in smoking cessation support (to 93.7%, England +0.1 pp) could reflect unverified recall capacity constraints.

    Cancer register and children's immunisation

    Cancer prevalence reached 6.0% (2,370 patients; England 3.8%). In Q1 2025/26 childhood immunisations, age 5 MMR dose 1 reached 95.8% (England 91.7%), but dose 2 dropped to 91.6% across 95 children, falling 3.4 pp below the 95.0% target. At The Petworth Surgery, dose 2 fell 23.1 pp below dose 1 (to 69.2% across 13 children). This pre-school drop-off indicates an opportunity for focused recall before school entry.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months95.5%

    England 91.0%

    6-in-1 complete primary course at 24 months92.7%

    England 92.2%

    MMR dose 1 at 24 months94.5%

    England 88.3%

    MMR dose 2 at age 591.6%

    England 82.8%

    4-in-1 pre-school booster at age 590.5%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    58.5%

    Sussex ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~1,360

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Sussex ICBEnglandNo usable stageStaged cancers
    Prostate56.6%53.2%19%1,668
    Breast86.1%85.4%23%1,400
    Bowel49.8%47.0%26%1,133
    Lung30.3%33.8%15%1,058
    Skin cancer95.3%87.8%17%698

    In 2022, 58.5% of cancers with a known stage in NHS Sussex ICB (4,799 of 8,209) were diagnosed at stage 1 or 2, above England (55.3%) but 16.5 pp below the 75.0% national ambition by 2028. Closing this gap would require about 1,360 extra early diagnoses annually across the ICB. Staged completeness was 64.3% (8,209 of 12,766 cases; England 67.0%). Early presentation varied from 24.1% for oesophagus to 86.1% for breast. These ICB figures describe system pathways rather than PCN performance. System-level diagnostic shortfalls mean primary care vigilance and early referral remain critical to improving stage distribution.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In Jul 2026, University Hospitals Sussex NHS Foundation Trust achieved 65.2% against the 85.0% 62-day referral to treatment standard, below Royal Surrey NHS Foundation Trust (84.5%), Portsmouth Hospitals University NHS Trust (75.2%), NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%). Its 28-day faster diagnosis standard was 74.0% (England 79.3%). Diagnostic 6-week waits reached 39.3% for colonoscopy and 45.4% for flexi sigmoidoscopy (England 30.8% and 32.1%). Hospital metrics do not measure PCN referral quality. Acute delays and endoscopy backlogs could delay definitive cancer management for referred PCN patients.

    Pathways within standard (%)SussexRoyal SurreyPortsmouthSurrey and Sussex ICBEngland
    28-day faster diagnosis (75%)74.0182.6266.8179.2979.32
    31-day treatment (96%)76.7996.4394.7890.4592.50
    62-day referral to treatment (85%)65.2084.4875.2071.5171.16
    Diagnostic waits over 6 weeks (%)SussexRoyal SurreyPortsmouthEngland
    MRI5.620.0050.3621.40
    CT8.570.1513.069.92
    Echocardiography0.391.5532.7528.48
    Colonoscopy39.350.0082.5230.83
    Gastroscopy20.020.0074.8829.02
    All 15 DM01 tests12.958.8251.9623.14
    Community services activityWest Sussex residentsSurrey and Sussex ICB
    Care contacts78,050309,615
    Referrals16,01566,930
    Patients with a contact19,77085,660

    Community services (residents of West Sussex), Jun 2026 (provisional). In Jun 2026, 72.7% of community service contacts among Chichester residents were with adults aged 65+ (56,740 of 78,050 contacts). These borough resident figures were not captured at PCN level. High community service usage among older people highlights an established network that could support cancer care and rehabilitation locally.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Patient satisfaction exceeds England, but phone access varies by 15.0 pp across practices

    In 2025/26, QOF overall achievement exceeded England (92.5%) across all four practices, from 92.6% at Pulborough Medical Group to 96.8% at Riverbank Medical Centre. Clinical domain scores reached 95.6% at Pulborough Medical Group to 100.0% at Riverbank Medical Centre, but vaccination and immunisation showed an 18.6 pp spread, from 53.0% at The Petworth Surgery to 71.6% at Riverbank Medical Centre.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Riverbank1190.071.2%75.3%96.0%
    Loxwood Surgery1160.075.8%76.0%92.9%
    Pulborough1280.066.3%72.2%89.0%
    Petworth1110.060.9%77.5%81.6%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNChichesterAssetPCNChichester
    Care homes (catchment)11 (465 beds)n/aSchools (catchment)62n/a
    Children's centres56Places of worship96153
    Libraries45Homelessness support (VCS)0no data
    Day centres (VCS)21Carers support groups (VCS)11
    Primary schools (LA maintained)2931Primary academies322
    Special schools21

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured annual asthma review recall

    64.4% of 2,666 asthma register patients had an annual review, trailing Chichester (67.5%) and England (65.7%), leaving 949 (about 950) unreviewed. For discussion: practices could run structured annual asthma recall using a single template and flexible slots, reviewing inhaler prescribing alongside review completion. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    COPD case-finding and review audit

    COPD prevalence is 1.8% (704 of 39,128 patients) vs 1.9% in Chichester and England (gap +37 to +56 patients); annual reviews fell 2.5% over 3 years. For discussion: practices could search for smokers or ex-smokers with repeated respiratory prescribing lacking a COPD code and run structured annual review recall. Moderate effort to run.

    Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.

    Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.

    Option 3

    Learning disability register validation

    Learning disability QOF prevalence is 0.4% (172 of 39,128 patients) versus 0.6% in Chichester and England, a benchmark gap range of +44 to +58 patients. For discussion: practices could audit clinical records for uncoded learning disability diagnoses and cross-check lists where social-care data sharing exists. Low cost, quick to run.

    Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.

    Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Older age capacity review (p2)Aged 65+Neighbourhood health framework · NHS vaccination strategyPCN
    Dispersed vulnerability outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI blood pressure recall audit (p4)Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs)MHIS · From Harm to HopePCN
    Hypertension monitoring recall audit (p5)Hypertension patients with a recent blood pressure readingCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school MMR second-dose recall (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Early cancer referral audit (p7)Cancers diagnosed at stage 1 or 2 (All cancer sites)—ICB
    Digital triage and access review (p9)GPPS easy to contact the practice using its website10YHP, hospital to communityPractice
    Option 1 · Structured annual asthma review recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 2 · COPD case-finding and review audit (p12)Registered population · COPD register · COPD: QOF prevalenceCore20PLUS5 approach · Tobacco and Vapes BillPCN
    Option 3 · Learning disability register validation (p12)Registered population · Learning disability register · Learning disability: QOF prevalence75% annual health checks (Network Contract DES) · Oliver McGowanPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026ICB2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15